Objectives and endpoints
RESIDUAL DISEASE
The main objective of this study is to improve the pathological response rate with sequential chemo-immunotherapy. The primary endpoint is the pCR rate, defined as the proportion of patients without residual disease in the surgical resection specimen (ypT0N0, 